You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 28, 2024

CLINICAL TRIALS PROFILE FOR SYNTOCINON


✉ Email this page to a colleague

« Back to Dashboard


All Clinical Trials for SYNTOCINON

Trial ID Title Status Sponsor Phase Start Date Summary
NCT00116480 ↗ Misoprostol in the Treatment of Postpartum Hemorrhage Completed Aga Khan Health Services N/A 2005-12-01 Postpartum haemorrhage (PPH) remains a leading cause of maternal mortality, despite treatment with conventional methods. Uncontrolled reports and three small randomised controlled trials have suggested that misoprostol may have an additive effect to routine treatment, and there is a serious danger that this method will be used widely without research to document the effectiveness or risks of this method. In this randomised controlled trial (RCT), we propose to test whether 600 μg of sublingually administered misoprostol in women requiring additional uterotonics after delivery, and after routine syntocinon to all women during or after delivery, has additional effects above the additional conventional uterotonics in reducing PPH. Women with measured blood loss greater than or equal to 500 mls in 4 Karachi hospitals who give consent will be given locally routine treatment for PPH. In addition, they will be enrolled by drawing the next of a series of randomised treatment packs containing misoprostol or placebo. The primary outcome measure will be blood loss greater than or equal to 500 mls after enrolment.
NCT00116480 ↗ Misoprostol in the Treatment of Postpartum Hemorrhage Completed Aga Khan University N/A 2005-12-01 Postpartum haemorrhage (PPH) remains a leading cause of maternal mortality, despite treatment with conventional methods. Uncontrolled reports and three small randomised controlled trials have suggested that misoprostol may have an additive effect to routine treatment, and there is a serious danger that this method will be used widely without research to document the effectiveness or risks of this method. In this randomised controlled trial (RCT), we propose to test whether 600 μg of sublingually administered misoprostol in women requiring additional uterotonics after delivery, and after routine syntocinon to all women during or after delivery, has additional effects above the additional conventional uterotonics in reducing PPH. Women with measured blood loss greater than or equal to 500 mls in 4 Karachi hospitals who give consent will be given locally routine treatment for PPH. In addition, they will be enrolled by drawing the next of a series of randomised treatment packs containing misoprostol or placebo. The primary outcome measure will be blood loss greater than or equal to 500 mls after enrolment.
NCT00116480 ↗ Misoprostol in the Treatment of Postpartum Hemorrhage Completed Family Care International N/A 2005-12-01 Postpartum haemorrhage (PPH) remains a leading cause of maternal mortality, despite treatment with conventional methods. Uncontrolled reports and three small randomised controlled trials have suggested that misoprostol may have an additive effect to routine treatment, and there is a serious danger that this method will be used widely without research to document the effectiveness or risks of this method. In this randomised controlled trial (RCT), we propose to test whether 600 μg of sublingually administered misoprostol in women requiring additional uterotonics after delivery, and after routine syntocinon to all women during or after delivery, has additional effects above the additional conventional uterotonics in reducing PPH. Women with measured blood loss greater than or equal to 500 mls in 4 Karachi hospitals who give consent will be given locally routine treatment for PPH. In addition, they will be enrolled by drawing the next of a series of randomised treatment packs containing misoprostol or placebo. The primary outcome measure will be blood loss greater than or equal to 500 mls after enrolment.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for SYNTOCINON

Condition Name

Condition Name for SYNTOCINON
Intervention Trials
Schizophrenia 11
Healthy 8
Postpartum Hemorrhage 7
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Condition MeSH

Condition MeSH for SYNTOCINON
Intervention Trials
Hemorrhage 23
Postpartum Hemorrhage 21
Autistic Disorder 12
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Locations for SYNTOCINON

Trials by Country

Trials by Country for SYNTOCINON
Location Trials
United States 70
Egypt 20
Canada 12
Israel 4
Denmark 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Trials by US State

Trials by US State for SYNTOCINON
Location Trials
California 17
Massachusetts 11
North Carolina 8
New York 8
Maryland 4
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Progress for SYNTOCINON

Clinical Trial Phase

Clinical Trial Phase for SYNTOCINON
Clinical Trial Phase Trials
Phase 4 16
Phase 3 13
Phase 2/Phase 3 4
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Status

Clinical Trial Status for SYNTOCINON
Clinical Trial Phase Trials
Completed 84
Unknown status 14
Recruiting 13
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Clinical Trial Sponsors for SYNTOCINON

Sponsor Name

Sponsor Name for SYNTOCINON
Sponsor Trials
Cairo University 13
University of California, San Francisco 12
Massachusetts General Hospital 9
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Sponsor Type

Sponsor Type for SYNTOCINON
Sponsor Trials
Other 198
U.S. Fed 14
NIH 10
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.